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662Bleeding after cardiac surgery remains a significant problem, increasing both length of stay and mortality, and is
caused bymultiple factors including dilutional changes, ongoing fibrinolysis, and platelet dysfunction. The eval-
uation of coagulopathy is problematic because of the long turnaround time of standard coagulation tests. Algo-
rithms involving point of care testing, including thromboelastography and thromboelastometry, have been
published; all have the potential to reduce transfusion requirements. Massive transfusion coagulopathy that oc-
curs in trauma can also be seen in complex aortic surgery and other massive bleeding patients and should prompt
consideration of a transfusion protocol involving fixed ratios of fresh frozen plasma, platelets, and red blood
cells. Pharmacologic agents such as antifibrinolytics are commonly administered, but a multimodal approach
to management is important. Recombinant and purified coagulation products are being studied and provide cli-
nicians specific agents to treat targeted deficiencies. A general multi-modal approach is required and recommen-
dations are made for the management of bleeding and coagulopathy in cardiac surgical patients. (J Thorac
Cardiovasc Surg 2011;142:662-7)Approximately5% to 7%of patients undergoing cardiac sur-
gery losemore than 2 L of chest tube drainage during the first
24 hours postoperatively, and up to 5% require reexploration
for bleeding, resulting in an increased length of stay and
higher mortality.1-3 Multiple causes, including activation of
the coagulation, fibrinolytic, and inflammatory pathways, di-
lutional changes, hypothermia, and other surgical factors,
contribute to this problem. Bleeding may also be further
exacerbated by perioperative use of various anticoagulants,
including heparin, thrombin inhibitors, and platelet inhibi-
tors. There is a complex equilibrium among red blood cells
(RBCs), platelets, coagulation factors, natural inhibitors of
coagulation, and the fibrinolytic system that is significantly
altered in cardiac surgery. Therefore, simple replacement of
blood volumes may not always be effective. This review
will focus on current therapies to treat bleeding after cardiac
surgery. An overview of the coagulation process, with
potential sites of intervention, is presented in Figure 1.LABORATORY TESTING AND USE OF
ALGORITHMS
Most studies demonstrate that transfusion algorithms re-
duce the need for platelets, fresh-frozen plasma (FFP), or
cryoprecipitate. However, any test that prevents empirical
administration likely will reduce this need.4 Most algo-
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The Journal of Thoracic and Cardiovascular Surgby a prothrombin time/activated partial thromboplastin
time more than 1.5 times normal, a platelet count less
than 50 to 100,000, or fibrinogen concentration less than
100 mg/dL (1 g/L).5 Measurement of D-dimers or fibrin
degradation products is also frequently done to see whether
fibrinolysis is occurring. Because most laboratory testing is
slow, point of care testing has been the focus of research as
recently reviewed.5 Thromboelastography and rotational
thromboelastometry are useful to determine fibrinolysis,
and thromboelastography or rotational thromboelastometry-
based algorithms have been shown to decrease blood product
use. However, the machines require quality-control follow-
up and are not available everywhere. Platelet function testing
has also been reported but is problematic because most tests
need a relatively high platelet count to work and may not be
applicable to post-cardiopulmonary bypass (CPB) platelet
dysfunction.TRANSFUSION THERAPY FOR BLEEDING
Volume replacement after cardiac surgery with critical
bleeding may require large fluid volumes. RBC transfusions
provide oxygen-carrying capacity, but crystalloids, colloids,
and RBCs provide neither coagulation factors nor platelets
and can exacerbate coagulopathy by dilution. Thrombocyto-
penia often follows volume replacement, and the inability to
evaluate platelet function complicates matters. Severe
bleeding requires FFP, platelets, cryoprecipitate, and poten-
tially factor concentrates (eg, fibrinogen and prothrombin
complex concentrates [PCCs]) to restore circulating levels
of hemostasis factors. Aftermassive transfusion therapy, hy-
pothermia and acidosis frequently occur, further complicat-
ing bleeding. Blood temperature and pH must be monitored
and corrected during any ongoing transfusion effort. Perio-
perative blood conservation guidelines in cardiac surgery
have been published, recommending institution-specificery c September 2011
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
FFP ¼ fresh-frozen plasma
FXIII ¼ Factor XIII
PCC ¼ prothrombin complex concentrate
RBC ¼ red blood cell
rFVIIa ¼ recombinant activated factor VIIa
TXA ¼ tranexamic acid
Sniecinski and Levy Perioperative Managementtransfusion algorithms, point-of-care testing, and a multi-
modal approach to coagulopathy treatment.6
Massive transfusion coagulopathy, generally defined as 10
RBCunits ormore transfused in a 24-hour period, is best stud-
ied from trauma literature. Because several blood volumes
may be replaced in these patients by the time results are avail-
able, laboratory testing is problematic.As a result, transfusion
protocols have been developed where fixed doses of FFP and
platelets are administered after a specific number of RBC
units have been given, often in a 1:1:1 ratio.4 Whether these
fixed ratios prevent coagulopathy is not established in cardiac
surgery, but in trauma and in noncardiac surgical battlefield
conditions, fixed transfusion ratios improve survival.7,8
Thus, with life-threatening hemorrhage, transfusion of fixed
ratios of RBCs, FFP, and platelets should be administered
when situations analogous to trauma situations are encoun-
tered, such as coagulopathy after complex aortic surgery.FIGURE 1. An overview of clot formation, demonstrating points of intervent
complex concentrates; AVP, arginine vasopressin; vWF, von Willebrand factor.
The Journal of Thoracic and CaANTIFIBRINOLYTIC AGENTS: LYSINE ANALOGS
The lysine analogs epsilon aminocaproic acid and tra-
nexamic acid (TXA) competitively inhibit activation of
plasminogen to plasmin, an enzyme that degrades fibrin
clots. TXA also inhibits plasmin at higher doses, and
most studies reported in cardiac surgery involve TXA. Ep-
silon aminocaproic acid does not consistently reduce trans-
fusion requirements or surgical reexploration.9 Multiple
meta-analyses of randomized controlled trials consistently
report a decrease in bleeding with these agents, but data re-
garding safety are limited. Postoperative convulsive sei-
zures at one institution were reported to increase from
1.3% to 3.8% after cardiac surgery, temporally coincident
with high-dose TXA.10 In 24 patients with postoperative
seizures, all received high doses of TXA intraoperatively
from 61 to 259 mg/kg, mean ages were 70 years, and 21
of 24 had open-chamber procedures.10 Although these
agents are typically used during CPB, additional use of
them should be considered postoperatively with evidence
of ongoing fibrinolysis.ANTIFIBRINOLYTIC AGENTS: APROTININ
Aprotinin, a polypeptide serine protease inhibitor, in-
hibits plasmin and other serine proteases. In cardiac surgery,
multiple randomized, placebo-controlled trials reported that
aprotinin reduced bleeding and allogeneic transfusions.11
However, recent reports from observational databases and
one randomized study questioned the safety of aprotinin.12ion. TF, Tissue factor; rFVIIa, recombinant factor VII; PCC, prothrombin
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MAfter publication of the BART study,13 Bayer Pharmaceuti-
cals (Montville, NJ) removed the drug from marketing, al-
though it is still available for compassionate use. Karkouti
and colleagues14 reported a retrospective single-center
cohort study of 15,365 cardiac surgical patients, of whom
1017 received aprotinin and 14,358 received TXA. They
noted aprotinin had a better risk-benefit profile than TXA
in high-risk, but not low- to moderate-risk, patients and sug-
gested its use in high-risk cases may be warranted. Other
synthetic serine protease inhibitors, such asCU-2010,which
possess antifibrinolytic activity comparable to aprotinin, are
currently under development.15PROTAMINE
Protamine is a polypeptide that contains approximately
70% arginine residues and inactivates the acidic unfractio-
nated heparin, but not low-molecular-weight heparin, mole-
cule via a simple acid-base interaction.16 Most patients
receive too much protamine for anticoagulation reversal
because fixed-dose regimens are based on initial or total hep-
arin dose and do not account for elimination. Excess prot-
amine should be avoided when reversing heparin because it
inhibits platelets and proteases, and potentially contributes
to coagulopathy.17 Maintaining heparin levels during CPB
and administering protamineon thebasis of the exact circulat-
ing heparin level reduced postoperative bleeding and transfu-
sions andproduced the lowest activatedclotting timevalues.18
Heparin rebound can occur after initial reversal and oc-
curs 2 to 3 hours later postoperatively.19 Heparin levels
with rebound may range from 0.1 to 0.3 IU/mL, suggesting
circulating levels of heparin, based on a 5-L blood volume,
of 500 to 1500 units. Protamine doses of 5 to 15 mg may be
effective at reversing heparin rebound rather than the 50 mg
commonly administered. The activated clotting time is not
a sensitive indicator of heparin rebound because platelet
counts and fibrinogen levels may also affect values.
Protamine can cause adverse reactions, including anaphy-
laxis, acute pulmonary vasoconstriction, right ventricular
failure, andhypotension.16Patients at an increased risk for ad-
verse reactions are sensitized, often from neutral-protamine-
Hagedorn insulin. Protamine reactions occur in 0.6% to 2%
of neutral-protamine-Hagedorn insulin–dependent diabetic
patients.20,21 Other individuals reported at risk for protamine
reactions include patients with vasectomy, multiple drug
allergies, and prior protamine exposure.16DESMOPRESSIN
Desmopressin (DDAVP; Sanofi-Aventis, Bridgewater,
NJ) is the V2 analog of arginine vasopressin that stimulates
von Willebrand factor multimers released from endothelial
cells. von Willebrand factor mediates platelet adherence to
vascular subendothelium by functioning as a protein bridge
between glycoprotein Ib receptors on platelets and subendo-664 The Journal of Thoracic and Cardiovascular Surgthelial vascular basement membrane proteins. Desmopres-
sin (DDAVP) shortens the bleeding time of patients with
mild forms of hemophilia A or von Willebrand’s disease.
Desmopressin (DDAVP) is administered intravenously
at a dose of 0.3 mg/kg over 15 to 30 minutes to avoid
hypotension.22
Most studies have not confirmed the early reported effi-
cacy during complex cardiac surgery, and a recent review
showed only a small effect on perioperative blood loss (me-
dian decrease, 115 mL).23 Because critically ill patients are
often receiving vasopressin, which also has V2- and V1-
mediated effects, there is little benefit to adding desmopres-
sin (DDAVP).FIBRINOGEN
Fibrinogen is an under-recognized coagulation factor crit-
ical for producing effective clot in surgical patients, and data
support it as a predictor of perioperative bleeding.24 Normal
fibrinogen levels are 200 to 400 mg/dL, although the target
fibrinogen level in a bleeding patient is not known. Bleeding
increases for each 100 mg/dL decrease in fibrinogen level in
parturient patients, who normally have levels more than 400
mg/dL,25 and low fibrinogen levels can predict bleeding
after prolonged CPB.26
Most transfusion algorithms recommend therapy when
fibrinogen levels are less than 100 mg/dL; however, low
fibrinogen levels can increase prothrombin time/partial
thromboplastin time that may not correct with FFP. In
this situation, cryoprecipitate or fibrinogen concentrates
are a better option to restore adequate plasma levels
(200 mg/dL) because they cause less hemodilution.
Fibrinogen can be repleted by cryoprecipitate; 1 unit/10 kg
increases fibrinogen by 50 to 70 mg/dL. In Europe, fibrino-
gen concentrates are available and cryoprecipitate is not
used. A fibrinogen concentrate (RiaSTAP; CSL Behring,
King of Prussia, Pa) has just been granted licensing as an or-
phan drug for treating bleeding in patients with congenital
afibrinogenemia or hypofibrinogenemia.RECOMBINANT COAGULATION PRODUCTS
Recombinant proteins are increasingly available for man-
aging bleeding, topical hemostasis, and other therapeutic
interventions. Recombinant proteins also can be modified
to alter specific characteristics that may be important in
therapeutic effects or provide quantities that can be admin-
istered supraphysiologically as a therapeutic agent. Cur-
rently, they are used to manage bleeding in patients with
hemophilia, von Willebrand‘s disease, or acquired anti-
bodies/inhibitors.Recombinant Activated Factor VIIa
Recombinant activated factor VIIa (rFVIIa; NovoSeven,
Novo Nordisk, Bagsværd, Denmark) is approved forery c September 2011
TABLE 1. Postoperative rescue therapy with off-label use of
recombinant factor VII in patients undergoing cardiac surgery30,31
 Severe (1 L/h) or life-threatening bleeding without surgical source of
bleeding
 Marginal response to routine hemostatic therapy (ie, platelets, FFP,
cryoprecipitate, desmopressin [DDAVP; Sanofi-Aventis, Bridgewater,
NJ])
 Administration with appropriate hemostatic factors present
 Consider lower doses than used in hemophilia (30–40 mg/kg)
 Use in patients with multiple antibodies to platelets; cross-match issues
when factors or platelets are not available
 Potential use for Jehovah’s Witnesses
Sniecinski and Levy Perioperative Managementpatients with hemophilia with inhibitors to treat bleeding
but is increasingly used off-label as a prohemostatic agent
for life-threatening hemorrhage.27 Only approximately
1% of circulating FVII is activated, and it has no effect until
bound with tissue factor. The prohemostatic effects of
rFVIIa are produced in part by complexing with tissue fac-
tor expressed at the vascular injury site to locally produce
thrombin and amplify hemostatic activation. Multiple pub-
lications report off-label rFVIIa use after cardiac surgery,
although the therapeutic rFVIIa dose in patients without he-
mophilia has not been established.
Thromboembolic complications with rVIIa use have
been reported to be 11.1%.28 However, the drug is typically
administered as rescue therapy to patients who have already
received multiple transfusions, have impaired coagulation,FIGURE 2. Management steps for treatment of excessive postoperative bleedin
of transfusion and reassessment of bleeding severity, and the decision to transfu
ratio protocols and off-label use of recombinant factor VIIa also needs to be d
cryoprecipitate; pRBCs, packed red blood cells; rFVIIa, recombinant factor VI
The Journal of Thoracic and Caand are at high risk for adverse events. Only arterial throm-
boembolic event rates were higher after rFVIIa versus
placebo (5.5% vs 3.2%) compared with venous thrombo-
embolic events (5.3% vs 5.7%), and were higher among
the elderly, likely reflecting the studies in intracranial
hemorrhage.28
In a recent cardiac surgical study, patients bleeding
more than 200 mL/h postoperatively were randomized to
placebo (n ¼ 68), 40 mg/kg rFVIIa (n ¼ 35), or 80 mg/kg
rFVIIa (n ¼ 69).29 The primary end points were critical
serious adverse events. Secondary end points included re-
operation rates, blood loss, and transfusions. Although
more adverse events occurred in the rFVIIa groups, they
did not reach statistical significance (placebo, 7%; 40
mg/kg, 14%; P ¼ .25; 80 mg/kg,12%; P ¼ .43). However,
after randomization, significantly fewer patients in the
rFVIIa group underwent a reoperation because of bleed-
ing (P ¼ .03) or required allogeneic transfusions
(P¼ .01).29 Guidelines for off-label use of rVIIa are given
in Table 1.30,31 A clinical protocol for bleeding incorpo-
rating the above concepts is presented in Figure 2.Factor XIII
Plasma factor XIII (FXIII) is an important final step in
clot formation that stabilizes the initial clot. Several
investigators have demonstrated reductions in FXIII during
CPB and an inverse relationship between postoperativeg without an identifiable surgical cause. Note that there is a continual cycle
se should not be based on laboratory values alone. Consideration of fixed
one when conventional measures fail. ACT, Activated clotting time; Cryo,
I.
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Mbleeding and FXIII levels. Plasma-derived FXIII (Fibro-
gammin; CSL Behring, Marburg, Germany) at the end of
CPB with concurrent antifibrinolytic therapy reduced
postoperative hemorrhage and transfusion requirement in
2 trials32,33 including 22 and 75 patients, respectively. The
addition of 2500 U FXIII (Fibrogammin) quickly restored
the plasma level of FXIII, as measured by Berichrom, to
70 or greater, and reduced transfusion requirements. A re-
combinant FXIII has been recently reported in clinical
studies, and more studies are under way to evaluate this
factor as a therapy to reduce bleeding.34
Prothrombin Complex Concentrates
PCCs are concentrates of coagulation factors that include
factors II, VII, IX, and X in variable concentrations.35
Two agents (eg, Beriplex P/N [CSL Behring] and Octaplex
[Octapharma, Vienna, Austria]) are approved outside the
United States for vitamin K antagonist-induced (ie, warfa-
rin) reversal and are being studied currently in the United
States. The PCCs available in the United States include
FEIBAVH (Baxter, Deerfield, Ill), Profilnine SD (Grifols,
Barcelona, Spain), and Bebulin VH (Baxter). They are ap-
proved for prevention and control of bleeding in patients
with hemophilia B and contain mainly factor IX.35 Only
FEIBA contains factor VII in an activated form, and Bebu-
lin contains only low levels of factor VII. In general, it is
considered preferable to give a PCC containing all 4
vitamin K-dependent coagulation factors and natural anti-
coagulants antithrombin and activated protein C for antico-
agulation reversal. Compared with FFP, PCCs provide
quicker international normalized ratio correction, have
a small infusion volume, and do not require crossmatching.
Although there are historical concerns about potential
thrombotic risk with PCCs, present-day PCCs are much
improved.
TOPICAL HEMOSTATIC AGENTS
Topical hemostatic agents are used intraoperatively to
promote hemostasis at the vascular injury site. They are
classified on the basis of their mechanism of action and
include physical or mechanical agents, caustic agents, bio-
logic physical agents, and physiologic agents.36 The agent
to use depends on the type of bleeding, the agent’s specific
mechanism of action, its interaction with the environment,
and the underlying coagulopathy.36 Absorbable agents
include gelatin sponges (Gelfoam; Pfizer, New York, NY),
derived from purified pork skin gelatin that increase contact
activation to help create topical clot. Surgicel (Ethicon,
Somerville, NJ) or Oxycel (Becton Dickinson Infusion
Therapy Systems, Sandy, Utah) is oxidized regenerated cel-
lulose that works like Gelfoam. Avitene (Davol, Warwick,
RI) is microfibrillar collagen derived from bovine skin. Col-
lagen sponges are available in different commercial forms
and are derived from bovine Achilles tendon or bovine666 The Journal of Thoracic and Cardiovascular Surgskin. Gelatin foam should not be used near nerves or in
confined spaces but can be administered topically with
thrombin. CoSeal (Baxter) is used where swelling and
expansion are not a concern. BioGlue (Bioform Medical,
San Mateo, Calif) has been used in cardiac surgery, but it
contains a glutaraldehyde component that cross-links
proteins and fixes the tissues to which it is applied.
Topically applied thrombin preparations are also used
extensively. The first available thrombin was derived from
bovine plasma (Thrombin-JMI, King Pharmaceuticals,
Bristol, Tenn). Bovine thrombin currently should be
avoided because of its potential for antibovine thrombin an-
tibody formation and immune-mediated coagulopathy.37
Currently, there are 2 human thrombins available for clini-
cal use, including plasma-derived thrombin (Evithrom;
Omrix, Somerville, NJ, and Johnson & Johnson, New
Brunswick, NJ) and recombinant human thrombin RECO-
THROM (ZymoGenetics, Inc, Seattle, Wash).
Fibrin sealants, also referred to as biological glue or fibrin
tissue adhesives, are component products that combine
thrombin (mostly human) and fibrinogen (usually plasma
derived). The first commercial fibrin sealant, Tisseel
(Baxter), was approved in 1989. Additional fibrin sealants
are currently in use, including Crosseal (Ethicon), Evicel
(Ethicon), and FloSeal (Baxter). They are packaged with
a dual-syringe delivery system that combines the compo-
nents to form a fibrin clot.36 The thrombin concentration de-
termines the onset and the tensile strength of the fibrin
seal.36 Crosseal contains human fibrinogen, human throm-
bin, and TXA. Evicel does not contain any fibrinolytic
inhibitors. Agents studied in cardiac surgery, including
FloSeal, are the subject of a recent review.38CONCLUSIONS
The potential for bleeding in patients undergoing cardiac
surgery represents an ongoing problem for clinicians. The
increasing use of anticoagulation agents creates a need for
multiple pharmacologic approaches. The growing use of
clopidogrel, prasugrel, and newer oral anticoagulants will
continue to pose new paradigms and potential problems in
managing surgical patients. Newer therapies, including
recombinant therapies, provide clinicians with the ability
to administer key coagulation proteins to treat hemorrhage
when standard therapies are ineffective.References
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